The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Drug: cyclosporine     Quarter: 2016Q3

Total Drug/Injury Combinations: 317     Number of Pages: 16

DRUGNAME PT EventCount
CYCLOSPORINE. Procalcitonin increased 1 view events
CYCLOSPORINE. Protein total decreased 1 view events
CYCLOSPORINE. Proteinuria 1 view events
CYCLOSPORINE. Pseudomonas infection 1 view events
CYCLOSPORINE. Psoriatic arthropathy 1 view events
CYCLOSPORINE. Pulmonary oedema 1 view events
CYCLOSPORINE. Rectal lesion 1 view events
CYCLOSPORINE. Respiratory failure 1 view events
CYCLOSPORINE. Respiratory syncytial virus infection 1 view events
CYCLOSPORINE. Reticulocyte count increased 1 view events
CYCLOSPORINE. Rhabdomyolysis 1 view events
CYCLOSPORINE. Rhinovirus infection 1 view events
CYCLOSPORINE. Seizure 1 view events
CYCLOSPORINE. Seminoma 1 view events
CYCLOSPORINE. Sepsis syndrome 1 view events
CYCLOSPORINE. Septic shock 1 view events
CYCLOSPORINE. Serum ferritin increased 1 view events
CYCLOSPORINE. Serum sickness 1 view events
CYCLOSPORINE. Shock 1 view events
CYCLOSPORINE. Skin hyperpigmentation 1 view events

Total Drug/Injury Combinations: 317     Number of Pages: 16

NOTE: EventCount numbers on this page include duplicate entries from event reports. (e.g. One event has DrugX entered twice, which equals 2 on this page.) The "view events" page treats these duplicates as single entries. (e.g. The 2 entries of DrugX for a single event are counted as 1 instance.)